健康人和骨肉瘤病人来源的LAK细胞体外抗瘤作用  

Effects of LAK Cells from Healthy Donors and Osteosarcoma Patients on Killing Transplanted Tumor Cells in vitro

作　　者：高苏宁[1] 周维江[1] 刘全海[1] 陈长玉[1] 

机构地区：[1]南京解放军第81医院骨科,上海第二军医大学长征医院骨科,上海医药工业研究院药理室

出　　处：《中国肿瘤临床》1996年第5期333-337,共5页Chinese Journal of Clinical Oncology

摘　　要：采用５１Ｃｒ释放试验对健康人和骨肉瘤病人外周血单个核细胞（ＰＢＭ）在重组白细胞介素－２（ｒＩＬ－２）条件下，ＬＡＫ细胞的诱导形成及对４种传代瘤细胞的体外杀伤活性进行探讨。实验结果表明：２种来源ＬＡＫ细胞对Ｋ５６２（人慢性髓样红白血病细胞系）、ＳＭＭＣ７７２１（人肝癌细胞系）、ＬＡＸ（人肺腺癌细胞系）的杀伤活性均在５５％以上（按效靶比例５０：１），而对ＯＳ细胞（人骨肉瘤细胞系）的活性普遍低下，杀伤率低于３５％。结果证实：１）健康人和骨肉瘤病人的ＰＢＭ均能在ｒＩＬ－２条件下诱导形成具有广谱抗瘤活性的ＬＡＫ细胞群，二者的杀伤格局和效力相近。２）骨肉瘤细胞本身对ＬＡＫ细胞的杀伤作用存在强烈抗性。The killing capacity of LAK cells against transplantable human K562, LAX, OS, SMMC7721 tumor cells in vitro was studied with 51Cr release assay. LAK cells were induced by rIL-2 from healthy donors and osteosarcoma patients' peripheral blood mononuclear cells. Our data showed that both of the LAK cells had a broad range of cytotoxicity toward the four tumor cell lines. The kinetics as to time. degree and effective duration of the LAK cells of the two sources were similar. The percentage of cytotoxicity of the LAK cells from the healthy donors and osteosarcoma patients were adove 55% for K562, LAX and SMMC7721 cell lines (at E: T ratio of 50: 1) but less than 35% for osteosarcoma cell line. This indicates that osteosarcoma cell line was strongly resistant to LAK cells.

关 键 词：RIL-2 LAK细胞 骨肉瘤细胞 肿瘤 生物疗法 

分 类 号：R730.51[医药卫生—肿瘤]